Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Next-Generation Sequencing in Medicine (Upcoming)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI119238

Oral tolerization to adenoviral antigens permits long-term gene expression using recombinant adenoviral vectors.

Y Ilan, R Prakash, A Davidson, . Jona, G Droguett, M S Horwitz, N R Chowdhury, and J R Chowdhury

Department of Medicine, Albert Einstein College of Medicine, Bronx, New York 10461, USA.

Find articles by Ilan, Y. in: JCI | PubMed | Google Scholar

Department of Medicine, Albert Einstein College of Medicine, Bronx, New York 10461, USA.

Find articles by Prakash, R. in: JCI | PubMed | Google Scholar

Department of Medicine, Albert Einstein College of Medicine, Bronx, New York 10461, USA.

Find articles by Davidson, A. in: JCI | PubMed | Google Scholar

Department of Medicine, Albert Einstein College of Medicine, Bronx, New York 10461, USA.

Find articles by Jona, .. in: JCI | PubMed | Google Scholar

Department of Medicine, Albert Einstein College of Medicine, Bronx, New York 10461, USA.

Find articles by Droguett, G. in: JCI | PubMed | Google Scholar

Department of Medicine, Albert Einstein College of Medicine, Bronx, New York 10461, USA.

Find articles by Horwitz, M. in: JCI | PubMed | Google Scholar

Department of Medicine, Albert Einstein College of Medicine, Bronx, New York 10461, USA.

Find articles by Chowdhury, N. in: JCI | PubMed | Google Scholar

Department of Medicine, Albert Einstein College of Medicine, Bronx, New York 10461, USA.

Find articles by Chowdhury, J. in: JCI | PubMed | Google Scholar

Published March 1, 1997 - More info

Published in Volume 99, Issue 5 on March 1, 1997
J Clin Invest. 1997;99(5):1098–1106. https://doi.org/10.1172/JCI119238.
© 1997 The American Society for Clinical Investigation
Published March 1, 1997 - Version history
View PDF
Abstract

Recombinant adenoviruses (Ads) efficiently transfer foreign genes into hepatocytes in vivo, but the duration of transgene expression is limited by the host immune response which precludes gene expression upon readministration of the virus. To test if this immune response can be abrogated by oral tolerization, we instilled protein extracts of a recombinant adenovirus type-5 via gastroduodenostomy tubes into bilirubin-UDP-glucuronosyltransferase-1 (BUGT1)-deficient jaundiced Gunn rats. Control rats received BSA. Subsequent intravenous injection 5 x 10(9) pfu of a recombinant adenovirus-expressing human BUGT1 (Ad-hBUGT1) resulted in hepatic expression of human BUGT1 (hBUGT1) with reduction of serum bilirubin levels by 70%. After 2 mo serum bilirubin increased gradually. In orally tolerized rats, but not in controls, a second dose of the virus on day 98 markedly reduced serum bilirubin again. In the tolerized rats, the development of antiadenoviral neutralizing antibodies and cytotoxic lymphocytes were markedly inhibited, and transplantation of their splenocytes into naive Gunn rats adoptively transferred the tolerance, indicating a role for regulatory cells. Lymphocytes from the tolerized rats hyperexpressed TGFbeta1, IL2, and IL4 upon exposure to viral antigens, whereas IFNgamma expression became undetectable. Thus, oral tolerization with adenoviral antigens permits long-term gene expression by repeated injections of recombinant adenoviruses.

Version history
  • Version 1 (March 1, 1997): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts